5 Best Biotech Stocks Under $10

In this article, we will look at the 5 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can read 10 Best Biotech Stocks Under $10.

5. CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Share Price as of September 23: $3.40

Number of Hedge Fund Holders: 23

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) develops therapeutics for the treatment of liver and other chronic diseases. The company’s flagship product is seladelpar, a potential treatment for primary biliary cholangitis. On June 6, Sujal Shah, CEO of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) disclosed his purchase of roughly 51,000 common shares of the company for a transaction valued at $0.10 million. As of September 23, CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has gained 7.3% over the past six months.

On August 1, CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced the successful enrollment for RESPONSE, the company’s global 52-week phase 3 study for evaluating seladelpar as a treatment for PBC. On August 11, CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced that it has $170.8 million worth in cash, cash equivalents, and securities, which will help the company stay on its operating plan through 2023.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is rising in popularity among institutional investors and is therefore one of the best biotech stocks to buy now. According to Insider Monkey’s database, 23 hedge funds were bullish on CymaBay Therapeutics, Inc. (NASDAQ:CBAY) at the end of Q2 2022. These funds held collective stakes of $107.25 million, up from $100 million in the previous quarter with 21 positions. The hedge fund sentiment for the stock is positive.

As of June 30, VenBio Select Advisor owns 10.3 million shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) and is the largest shareholder in the company. The fund’s stakes are valued at $30.38 million.